ADA: J&J's Invokana and rivals cut heart failure hospitalizations without increasing amputation risk

ADA: J&J's Invokana and rivals cut heart failure hospitalizations without increasing amputation risk

Source: 
Fierce Pharma
snippet: 

Johnson & Johnson's Invokana is alone in the class of SGLT2 diabetes drugs in carrying a boxed warning detailing amputation risks, but a new real-world analysis of more than 700,000 patients found the medication and other SGLT2 drugs lowered heart failure hospitalizations without increasing those risks.